

CONSUMER HEALTHTECH

2024 MARKET REPORT AND A LOOK AHEAD INTO 2025

To be added to the distribution, please contact eric.bormel@solomonpartners.com

AN AFFILIATE OF


~

_ ຕ




Private and Confidential

COVERAGE ACROSS THE CONSUMER HEALTHTECH UNIVERSE



Note: Companies are representative of the 1,000+ companies that participate in the Solomon-defined sector.

COVERAGE ACROSS THE CONSUMER HEALTHTECH UNIVERSE (CONT'D)





LOOKING AHEAD



S cale proved to be the defining characteristic of 2024 in Consumer Healthtech. The big got bigger, while underleveraged operations sought transformative partnerships to compete. Collectively, this led to another robust year of growth in Consumer Healthtech: 11% scaled public company median stock price increase ^(a), 37% venture funding increase and 9% scaled M&A increase. As the leading M&A investment bank for the category, we identified key themes of 2024 and what it means for 2025:

Flight to Scale, Margin and Growth

In 2023, cash flow was king. In 2024, we observed a rotation back into profitable growth. Anchored by the Rule of 40, companies

above the 'threshold 40%' level demonstrated multiple expansion compared to those under 40% (Exhibit A) Underpinned by marke leadership, economies of scale and durable gross margins these 2024 winners largely

el	Rule of		EV/CY+1 Rev
e	40 ^(b)	#	Dec-24 Dec-23
e).	50%+	4	6.5 x 🔶 5.7 x
ı. t	40%-50%	8	4.5 x 🔶 3.7 x
2	30%-40%	12	2.5 x 🔶 3.1 x
5.	15%-30%	13	2.0 x 🔶 2.3 x
,	0%-20%	6	0.9 x 🔶 3.5 x

avoided macro-headwinds from Large-Cap Tech (Apple hearing aids / bundling, Google AI-driven SEO, etc.) and Big Pharma (GLP-1 impact). This rotation was hardest for those subscale – 25 of 31 subscale companies experienced a stock price decline in 2024 ^(c). Notably, with select exceptions, we did not observe public Consumer Healthtech companies leverage M&A to drive growth. Given these themes around the importance of scale and growth, we expect public companies to revisit acquisitions in 2025 as a core use of capital, especially as higher quality opportunities come to market.

Funding Resurgence

Consumer Healthtech funding surged to \$6.3 billion, up 37% over 2023 and near 2022 levels, driven by a 53% increase in the number of financings over \$30 million. Credit the Tech-Enabled Care Management vertical, which returned to prominence with another year of favorable employer data (*Talkiatry, Sword, Maven, Glooko, Spring* each raised over \$100 million). However, without a clear public market exit from this vertical in 2023 or 2024 and with existing public peers trading lower, we expect late-stage capital in Tech-Enabled Care Management to *hinge* on the ability for existing venture investors to demonstrate ROI from a multibillion public market or M&A exit, while other verticals continue to attract late-stage venture capital at modest increases.

Private Equity's Moment

Industry maturation is directly leading to Private Equity participation. With 13 platform acquisitions, up from 9 in 2023, Private Equity's involvement drove scaled M&A to 36 for the year. Thematically this was driven by Virtual Care with *Sunstone, Kayne Anderson* and *Pharos* each placing new platform investments, with additional vertical investments from *HIG, Inverness Graham, Lightyear, Altaris, Heritage, FTV, Platinum, Bansk, Falfurrias, Grant Avenue and FS Investments* ^(d). We view this Private Equity moment as early days of a long arc towards the category as Consumer Healthtech experiences traditional PE tailwinds (strong but moderating organic growth, durable retention, inorganic add-ons, etc.).

Scaling Up

While the chasm between healthcare and consumer is closing with innovative Consumer Healthtech solutions, the costs to participate in both enterprise and consumer acquisition channels create burn challenges for most subscale businesses. We observed several stock-for-stock transactions in 2024 – including at least one in each vertical – that address this obstacle. In 2025, we expect this trend to magnify given the extended hold periods for assets in PE / VC portfolios along with the known benefits of scale to bolster operating leverage.

Closing Thoughts

Amidst a resurging 2024 environment, we are proud to have served as financial advisor on two Consumer Healthtech transactions. We thank our clients for entrusting us to guide them through these monumental moments in their Company – across sellside, buyside, capital raises and debt advisory engagements.

Consumer Healthtech brings together the most innovative Digital Health companies with Wellness and Fitness Technologies that together improve health outcomes, bend the cost curve and / or bring health equity to our system while delivering returns for shareholders. Daily, we talk with entrepreneurs, founders, strategic executives and Private Equity investors seeking angles and opportunities in Consumer Healthtech; it brings us such joy to support this category.

Please enjoy our 2024 Consumer Healthtech Market Report. As we enter 2025, we'd welcome a chance to connect – either inperson or virtually – and look forward to a fruitful and active year.

Regards,

Eric Bormel Director, Consumer Healthtech

Source: See following pages for support and definition of public companies and transactions.

(a) Includes 23 public Consumer Healthtech companies with greater than \$2 billion market cap as of December 31, 2024, as defined in the report.
(b) Rule of 40 defined as 'CY23-CY25 Revenue CAGR + CY25 EBITDA Margin'.

 ⁽c) Includes public Consumer Healthtech companies with less than \$2 billion market cap as of December 31, 2024, including Micro-Cap companies as defined in the report.
(d) Includes Private Equity acquirors whose platform acquisitions are not considered 'scaled', as defined in the report.

TABLE OF CONTENTS



Section

PUBLIC COMPANY OPERATING & VALUATION UPDATE

March April May June July August Septembe

2024 INDICATORS



M&A INDICATORS

M&A accelerated driven by Private Equity interest in the category, offset by a slowdown in public M&A



FINANCING INDICATORS

Return to funding levels in 2022 seen across Consumer Healthtech in B2B2C and B2C opportunities



PUBLIC COMP INDICATORS

Scale differentiated the total return for many Consumer Healthtech companies as 25 of 31 subscale companies saw stock price decline ^(a)

> +11% Stock Price Return 2024 Scaled Median ^(b)

-9% Stock Price Return All 47 Consumer Healthtech Companies



OPERATIONAL INDICATORS

Consumer Healthtech remains a high growth category and with companies increasingly generating robust cash flow

> +15% Revenue Growth 2024 Mean

+550 EBITDA Margin 2023-2025 Mean Basis Point Expansion

+9% # of Transactions 2024 vs. 2023

+44%

PE Involvement 2024 vs. 2023 Platform Acquisitions +28% # of Transactions 2024 YoY

> +37% **\$ Raised** 2024 YoY

SOLOMO PARTNERS Source: See following pages for support and definition of each group of public companies and transactions.

(a) Includes public Consumer Healthtech companies with less than \$2 billion market cap as of December 31, 2024, including Micro-Cap companies as defined in the report.

(b) Includes 23 public Consumer Healthtech companies with greater than \$2 billion market cap as of December 31, 2024, as defined in the report.

M&A ACTIVITY

9% INCREASE IN M&A ACTIVITY DRIVEN BY PRIVATE EQUITY INTEREST IN VIRTUAL CARE


SUMMARY M&A ACTIVITY (#) SELECTED TRANSACTIONS 2024 2023 YOY DARIO LIGHTYEAR Sprightside Health 👼 Care Management 3 2 50% **Cura**linc **lionrock** ~twill Vitality <u>CPS</u> GRAHAM zetlis URBAN SPORTS CLUB TELUS | HEALTH ALTARIS H. I. G. Corporate Wellness 8 8 CABITA WellSpark **benify** myclubs C HUMANOO O BenefitHub M mobilehealth 😰 CloudMD ĸ **WEDICAL** GUARDIAN fabric ⊕ HUMA LetsGet O Zinial Therapeutics SUNSTONE KAYNE ANDERSON Virtual Care 13 8 63% TeleMed2U Truepill • MeMD **AKILI** accuhealth. GRANT≥ Avenue Owens &Minor Platinum Equity HERITAGE GROUP Consumer Med Tech 5 5 --Performance Nationwide ROTECH VALD Home Medical Medical **WebMD** H. I. G. Outside \heartsuit Health Wellness Tech 3 5 (40%) healthwise **↓** healthe **MAPMYFITNESS** Bansk TOMMIE o COPPER IOHNSON **Connected Health** 5 4 (20%)**Fitness Devices** CORE FOUNDATION PRºFOOT. BOWFLEX (Acq) Total 33 9% 36 (Tar)

SOLOMON PARTNERS

Source: Press releases, public filings and company websites of Consumer Healthtech companies, as defined on page 2 and 3. Excludes non-advisor M&A transactions with Enterprise Value less than \$75 million Note: YoY represents Year over Year growth. Selected Transactions ordered by announce date.



AFTER A FAST START, MOMENTUM SLOWED IN Q4 2024 DUE TO UNCERTAINTY AROUND THE U.S. POLITICAL AND INTEREST RATE ENVIRONMENT





FINANCING ACTIVITY

263 FINANCINGS OCCURRED RAISING \$6.3 BILLION IN 2024, SHARPLY HIGHER THAN 2023

SUMMARY FINANCING ACTIVITY (#) **# OF TRANSACTIONS** \$ RAISED (\$M) 2024 YOY YOY 2024 \mathcal{X} glooko **9** foodsmart **Talkiatry** sword Spring Health 🖉 Care Management 80 29% 2,070 34% MAVEN \$100 \$200 \$130 \$130 \$125 \$100 seda bwell 🔊 Thatch 🚺 transcarent Realthee minu 4 Corporate Wellness health 27 13% 520 13% \$50 \$38 \$32 \$126 \$40 \$30 doc ⊕ H U M A (k)genome Function COACHCARE J.S. Virtual Care 58 14% 12% 1.350 \$75 \$53 \$300 \$80 \$50 \$48 **O** health CALA **βetα** βionics **Avive** X 🐨 kestra Consumer Med Tech 32 100% 117% 890 \$196 \$60 \$60 \$57 \$50 \$45 Flo STRAVA 🙆 Nourish 🔹 Turquoise Health Headway Natural Cycles^o \bigcirc Health & Wellness Tech 35 57% 9% 800 \$200 \$100 \$75 \$55 \$45 \$35 **R** ULTRAHUMAN Connected Health & niloid 🛟 MOVANO EZPO OXEFIT EGYM **ŌURA** 32 700 40% 60% **Fitness Devices** \$200 \$200 \$58 \$25 \$24 \$21 Total 264 28% 6,330 37%

OLOMON PARTNERS

🖕 grow therapy

\$88

merntive

\$25

doccla

\$46

NOCTRIX

\$40

\$30

\$18

two chairs

\$72

SCRIPTA

\$17

COCTAGOSHealt

\$43

Cognito Therapeutics

\$35

Carewell

\$25


elvie

\$12

TOP 8 TRANSACTIONS (\$M)


FINANCING ACTIVITY

THE VENTURE MARKET ECLIPSED THE NUMBER OF TRANSACTIONS IN 2022 AND NEARLY ACHIEVED FUNDING LEVELS IN 2022 LED BY A RESURGENCE IN CARE MANAGEMENT AND CONSUMER MED TECH






PUBLIC COMPANIES FINISHED 9% LOWER IN 2024 AS FORWARD EBITDA MULTIPLES CONTRACTED BY 1.6x




SOLOMON PARTNERS Source

REVENUE GROWTH SLIGHTLY DECELERATED IN 2024 AS PUBLIC COMPANIES PRIORITIZED MARGIN EXPANSION





VALUATION MULTIPLES INCREASINGLY ALIGNED TO RULE OF 40 VALUATION METHODOLOGY AS INDUSTRY MATURES





Source: Median of Public Filings and Capital IQ as of December 31, 2024. See following pages for support and definition of each group of public companies. a) Rule of 40 defined as CY23-CY25 Revenue CAGR + CY25 EBITDA Margin compared to EV / CY25 Revenue and EV / CY25 EBITDA. b) Rule of 40 defined as CY22-CY24 Revenue CAGR + CY24 EBITDA Margin compared to EV / CY24 Revenue and EV / CY24 EBITDA.

	Price	Stock P	rice Perforı	nance	Equity	Enterprise	Revenue	% Rev (Growth	EV / Re	evenue	Gross	Margin	EV / E	BITDA
Company Name	12/31/24	3-Mo	6-Mo	LTM	Value	Value	CY2024	CY2024	CY2025	CY2024	CY2025	CY2024	CY2025	CY2024	CY2025
Corporate Wellness	& Care Mana	gement													
Accolade	\$3.21	(17%)	(10%)	(73%)	\$263	\$238	\$439	13%	15%	0.5 x	0.5 x	50%	51%	NM	8.3 x
HealthEquity	92.88	13%	8%	40%	7,933	8,692	1,193	19%	8%	7.3 x	6.7 x	66%	68%	18.2 x	16.0 x
Optima Health	1.87	(2%)	IPO	IPO	166	170	133	(6%)	7%	1.3 x	1.2 x	33%	33%	7.6 x	7.6 x
Progyny	14.10	(16%)	(51%)	(62%)	1,235	999	1,144	5%	1%	0.9 x	0.9 x	22%	22%	5.2 x	5.1 x
Mean		(5%)	(18%)	(32%)				8%	8%	2.5 x	2.3 x	43%	43%	10.3 x	9.3 x
Median		(9%)	(10%)	(62%)				9 %	8 %	1.1 x	1.0 x	41 %	42 %	7.6 x	7.9 x
Size Weighted Mea	an (a)	9 %	(0%)	23%				12%	7 %			45%	46 %		
<u>Virtual Care</u>															
Apotea	\$7.36	IPO	IPO	IPO	\$772	\$789	NA	NA	NA	NA	NA	NA	NA	NA	NA
DocGo	4.25	28%	38%	(24%)	437	392	626	1%	(31%)	0.6 x	0.9 x	35%	35%	5.4 x	10.1 x
Hims & Hers	26.14	42%	29%	194%	6,238	5,984	1,463	68%	39%	4.1 x	2.9 x	80%	79%	33.9 x	22.5 x
Kooth	2.13	(48%)	(43%)	(43%)	78	59	83	97%	2%	0.7 x	0.7 x	80%	76%	3.9 x	3.8 x
LifeMD	4.92	(6%)	(28%)	(41%)	224	207	206	39%	24%	1.0 x	0.8 x	90%	90%	15.6 x	7.1 x
ModivCare	10.87	(24%)	(59%)	(75%)	168	1,339	2,802	2%	7%	0.5 x	0.4 x	15%	16%	7.8 x	7.1 x
Talkspace	3.07	47%	33%	21%	522	403	188	26%	24%	2.1 x	1.7 x	46%	45%	NM	23.0 x
Teladoc	9.27	1%	(5%)	(57%)	1,629	1,926	2,566	(1%)	(1%)	0.8 x	0.8 x	71%	71%	6.0 x	6.0 x
WELL Health	4.87	57%	48%	81%	1,217	1,497	691	28%	12%	2.2 x	1.9 x	44%	45%	16.9 x	14.4 x
Mean		12%	2 %	7 %				32 %	9 %	1.5 x	1.3 x	58 %	57 %	12.8 x	11.7 x
Median		14%	12%	(32%)				27 %	9 %	0.9 x	0.9 x	59%	58 %	7.8 x	8.6 x
Size Weighted Mea	an (a)	34%	24 %	113%				46 %	25%			70 %	70 %		



	Price	Stock P	rice Perfor	mance	Equity	Enterprise	Revenue	% Rev C	Growth	EV / Re	evenue	Gross	Margin	EV / E	BITDA
Company Name	12/31/24	3-Mo	6-Mo	LTM	Value	Value	CY2024	CY2024	CY2025	CY2024	CY2025	CY2024	CY2025	CY2024	CY2025
<u>Consumer Med Tech</u>															
<u>Sleep Health</u>															
Inspire Medical	\$185.72	(12%)	39%	(9%)	\$5,603	\$5,192	\$796	27%	19%	6.5 x	5.5 x	84%	85%	36.3 x	31.3 x
Nyxoah	8.13	(8%)	19%	82%	306	256	6	24%	459%	NM	8.1 x	63%	67%	NM	NM
ResMed	231.50	(5%)	21%	35%	33,783	34,018	4,826	7%	9%	7.0 x	6.4 x	60%	60%	20.2 x	17.8 x
SomnoMed	0.27	8%	70%	(14%)	59	53	62	11%	12%	0.8 x	0.8 x	NA	NA	23.5 x	10.8 x
<u>Diabetes</u>															
DexCom	75.29	12%	(34%)	(39%)	29,396	29,402	4,019	11%	15%	7.3 x	6.4 x	63%	65%	25.3 x	20.6 x
Insulet Corp	256.93	10%	27%	18%	17,988	18,484	2,057	21%	18%	9.0 x	7.6 x	69%	70%	42.0 x	34.7 x
iRhythm Technologies	85.95	16%	(20%)	(20%)	2,690	2,814	584	19%	16%	4.8 x	4.1 x	69%	70%	NM	NM
Senseonics	0.43	23%	8%	(25%)	242	259	22	(2%)	56%	11.8 x	7.5 x	10%	24%	NM	NM
Tandem Diabetes	32.86	(23%)	(18%)	11%	2,167	2,042	908	21%	11%	2.3 x	2.0 x	51%	53%	NM	NM
<u>Rehabilitation</u>															
Enovis	42.29	(2%)	(6%)	(25%)	2,418	3,731	2,100	23%	6%	1.8 x	1.7 x	59%	60%	9.9 x	9.0 x
<u>Hearing</u>															
Amplifon	25.60	(5%)	(27%)	(22%)	5,860	7,491	2,519	6%	9%	3.0 x	2.7 x	79%	79%	12.5 x	11.2 x
Demant	36.28	(1%)	(14%)	(13%)	8,113	10,200	3,150	(0%)	7%	3.2 x	3.0 x	77%	76%	12.5 x	11.6 x
GN	18.37	(13%)	(33%)	(24%)	2,773	4,242	2,513	(1%)	3%	1.7 x	1.6 x	53%	55%	10.5 x	8.7 x
Masimo	170.28	28%	35%	45%	9,136	9,750	2,087	2%	6%	4.7 x	4.4 x	53%	54%	24.7 x	21.9 x
Sonova	327.79	(4%)	5%	7%	19,802	21,377	5,295	30%	(14%)	4.0 x	4.7 x	73%	73%	19.5 x	17.6 x
Vision															
Bausch+Lomb	18.20	(6%)	25%	7%	6,424	10,796	4,767	15%	6%	2.3 x	2.1 x	63%	63%	12.3 x	11.1 x
EssilorLuxottica	241.85	9%	15%	27%	112,244	123,101	27,599	4%	7%	4.5 x	4.2 x	64%	64%	17.5 x	15.9 x
Kits Eyecare	6.00	(16%)	0%	38%	190	185	111	32%	23%	1.7 x	1.4 x	33%	34%	NM	28.2 x
Warby Parker	24.06	47%	50%	71%	2,853	2,602	768	15%	13%	3.4 x	3.0 x	55%	55%	35.7 x	28.0 x
<u>Wearables (Other)</u>															
Align Technology	214.52	(16%)	(11%)	(22%)	15,878	14,836	4,006	4%	6%	3.7 x	3.5 x	71%	70%	14.9 x	13.7 x
Mean		2 %	8 %	6 %				13%	34%	4.4 x	4.0 x	60 %	62 %	21.2 x	18.3 x
Median		(3%)	6%	(1%)				13%	10%	3.7 x	3.8 x	63%	64 %	19.5 x	16.8 x
Size Weighted Mean	i (a)	4 %	8 %	12%				9 %	7 %			65 %	65 %		



	Price	Stock P	rice Perfori	mance	Equity	Enterprise	Revenue	% Rev (Growth	EV / Re	evenue	Gross	Margin	EV / E	BITDA
Company Name	12/31/24	3-Mo	6-Mo	LTM	Value	Value	CY2024	CY2024	CY2025	CY2024	CY2025	CY2024	CY2025	CY2024	CY2025
Health & Wellness Te	<u>ech</u>														
Doximity	\$53.41	23%	91%	90%	\$9,743	\$8,938	\$516	14%	12%	17.3 x	15.5 x	92%	91%	35.3 x	31.0 x
GoHealth	12.31	31%	27%	(8%)	125	756	744	(9%)	7%	1.0 x	1.0 x	82%	83%	9.1 x	7.4 x
GoodRx	4.41	(36%)	(43%)	(34%)	1,682	1,749	794	5%	4%	2.2 x	2.1 x	94%	94%	6.7 x	6.3 x
Sleep Cycle	3.38	(18%)	0%	(4%)	69	58	24	11%	25%	2.4 x	1.9 x	77%	78%	7.7 x	7.4 x
WW International	1.48	69%	26%	(83%)	115	1,487	775	(13%)	(8%)	1.9 x	2.1 x	68%	68%	10.8 x	10.7 x
Ziff Davis	55.68	14%	1%	(17%)	2,375	2,853	1,413	3%	5%	2.0 x	1.9 x	86%	85%	5.6 x	5.3 x
Mean		14%	17%	(9%)				2%	7 %	4.5 x	4.1 x	83%	83%	12.6 x	11.3 x
Median		19 %	14%	(12%)				4%	6 %	2.1 x	2.0 x	84 %	84 %	8.4 x	7.4 x
Size Weighted Mea	an (a)	14%	58 %	55%				10%	10%			91 %	90 %		
Connected Health &			700/	1/50/	\$559	¢rca	¢107	100/	77 0/			000/	000/	75 2 2	251.4
Catapult Group	\$2.13	39%	79%	145%	•	\$562	\$103	18%	23%	5.5 x	4.4 x	80%	80%	35.2 x	25.1 x
Garmin InBody	207.61 15.16	18%	27%	62%	39,601 194	36,071 125	6,136 139	19% 17%	9% 9%	5.9 x 0.9 x	5.4 x 0.8 x	59% 77%	58% 76%	21.6 x	19.8 x 3.2 x
Johnson Health Tech		(12%) 15%	(16%) 104%	(14%) 163%			1,452	24%					76% 51%	3.9 x	
	5.56 0.80		0%	(56%)	1,686 367	2,174 166	313	1%	13% 7%	1.5 x 0.5 x	1.3 x 0.5 x	50% 46%	48%	14.2 x NM	11.3 x NM
Keep Fitness Owlet	4.46	(21%) (1%)	8%	(16%)	72	73	74	38%	20%	0.5 x 1.0 x	0.5 x 0.8 x	46%	48% 50%	NM	NM
Peloton	9.54	104%	182%	57%	3,601	4,378	2,568	(4%)	(4%)	1.0 x 1.7 x	1.8 x	48%	48%	39.3 x	17.0 x
Technogym	10.84	104%	7%	14%	2,196	2,104	2,308	(4 <i>%</i>) 10%	(4%) 8%	2.3 x	2.1 x	49% 59%	48 <i>%</i> 60%	11.7 x	17.0 x 10.6 x
	10.04				2,190	2,104	920								
Mean		19%	49 %	44%				15%	11%	2.4 x	2.1 x	59 %	59 %	21.0 x	14.5 x
Median		13%	18%	35%				17 %	9 %	1.6 x	1.6 x	54%	54%	1 7.9 x	14.2 x
Size Weighted Mea	an (a)	24 %	<mark>41%</mark>	62%				13%	7 %			56%	55%		
All Consumer Health	ntech - 47 Co	<u>mpanies</u>													
Mean		8 %	13%	9 %				15%	20 %	3.4 x	3.1 x	61 %	62 %	17.3 x	14.4 x
Median		0%	8 %	(9%)				12%	9 %	2.2 x	2.1 x	63 %	64 %	14.2 x	11.2 x
Size Weighted Mea	an (a)	8%	14%	24 %				10%	7 %			62 %	63 %		
Cumulative \$ Grow	/th							9 %	7 %			11%	7 %		



	Price	Stock Pi	rice Perfori	mance	Equity	Enterprise	Revenue	% Rev (Growth	EV / Re	evenue	Gross	Margin	EV / E	BITDA
Company Name	12/31/24	3-Mo	6-Mo	LTM	Value	Value	CY2024	CY2024	CY2025	CY2024	CY2025	CY2024	CY2025	CY2024	CY2025
Micro-Cap (Defined a	as Market Ca	<u>p Betweer</u>	<u>1910M and</u>	\$50M or N	egative En	terprise Valu	<u>e)</u>								
<u>Corporate Wellness &</u>	<u>& Care Manag</u>	<u>ement</u>													
DarioHealth	\$0.70	(38%)	(41%)	(59%)	\$22	\$35	\$27	32%	43%	1.3 x	0.9 x	58%	65%	NM	NM
LifeSpeak	0.25	(28%)	(6%)	(45%)	15	70	34	(8%)	4%	2.1 x	2.0 x	89%	90%	9.1 x	7.3 x
Virtual Care															
American Well	7.85	(17%)	21%	(74%)	120	(111)	250	(4%)	25%	NM	NM	36%	50%	NM	NM
Consumer Med Tech															
Nuheara	0.05			(30%)	12	12	NA	NA	NA	NA	NA	NA	NA	NA	NA
Vivos Therapeutics	4.70	80%	112%	(62%)	22	16	15	10%	26%	1.0 x	0.8 x	61%	63%	NA	NA
<u>Health & Wellness Te</u>	<u>ch</u>														
23andMe	3.17	(54%)	(59%)	(83%)	81	(45)	NA	NA	NA	NA	NA	49%	48%	NA	NA
Beachbody	6.50	14%	(23%)	(22%)	43	31	414	(20%)	(18%)	0.1 x	0.1 x	68%	68%	1.3 x	1.5 x
Connected Health &	Fitness Device	es													
Movano	5.96	11%	44%	(49%)	38	27	2	NA	545%	11.2 x	1.7 x	55%	55%	NA	NA
Zepp Health	2.80	(36%)	16%	(51%)	42	46	177	(49%)	19%	0.3 x	0.2 x	40%	41%	NM	NM
Delisted in 2024 Invitae	<u>Status</u> 2/13/24: File	s Chapter 1	1 bankuptc	V											

Invitae 2/13/24: Files Chapter II bankuptcy 2/16/24: Acquired by Patient Square Capital Eargo Bowflex 5/4/24: Files Chaprter 11 bankruptcy ProSomnus 5/8/24: Files Chapter 11 bankruptcy 5/29/24: Filed Chapter 7 bankruptcy Cue Health 7/2/24: Acquired by Virtual Therapeutics Akili Therapeutics 10/10/24: Delisted to OTCQB Biotricity Sharecare 10/22/24: Acquired by Altaris





SOLOMON CONSUMER HEALTHTECH COVERAGE

ABOUT US

SOLOMON PARTNERS IS AN INDEPENDENTLY OPERATED INVESTMENT BANK WITH PROPRIETARY ACCESS TO GLOBAL FINANCING CAPABILITIES AND INTERNATIONAL COVERAGE THROUGH OUR PARENT COMPANY, NATIXIS

- Founded in 1989, we are a leading financial advisory firm with a legacy as one of the first independent investment banks
- We offer unmatched industry knowledge in the sectors we cover, providing comprehensive strategic solutions tailored to generate long-term shareholder value
- We offer the "best of both worlds": the experience of a boutique culture with the international reach and capabilities of a global institution

CAPABILITIES

Capital Raising

We help companies

raise capital in both public

and private markets across

the capital structure

Mergers & Acquisitions

We advise clients on public and private mergers, acquisitions, divestiture, spinoffs and other strategic advisory assignments

Capital Advisory

We work closely with our clients to understand their critical issues and providing solutions to transform balance sheets





THE NATIXIS GLOBAL NETWORK

We provide our clients access to **strategic advisory services** and proprietary financing capabilities throughout the Americas, Europe and Asia Pacific.


- Natixis network with local presence in 35+ countries
- **Coverage** for all major continents

US TEAM

175+

Professionals

• Significant **cross-border** M&A and capital raising





CONSUMER HEALTHTECH LEADERSHIP

CONSUMER HEALTHTECH EFFORT SUPPORTED BY SOLOMON'S WELL-CONNECTED NETWORK OF STRATEGIC AND SPONSOR RELATIONSHIPS ACROSS HEALTHCARE, CONSUMER RETAIL, TECHNOLOGY & MEDIA INDUSTRIES

HEALTHO	CARE	CONSUMER RETAIL	TECHNOLOGY	MEDIA
Eric Bormel Consumer Healthtech	Jon Hammack Head of Healthcare Med Tech	David Shiffman Head of Consumer Retail	Craig Muir Head of Data, Software & Analytics	Mark Boidman Head of Media
(m) 786.831.6614 Eric.Bormel@solomonpartners.com	Karan Garg Healthcare Services	Jon LeVert Consumer	Jeff Derman Data, Software & Analytics	Ben Zinder Media
11+ Years of Experience				
Select Company Clients	Whit Knier Healthcare Services	Adam Jaffe Experiential, Leisure & Lifestyle	Joe Watson Data, Software & Analytics	Rich Brail Chairman of M&A
mapmy@fitness	Aryeh Sand Life Sciences	Brandon Yoshimura Direct-to-Consumer	James Butcher Data, Software & Analytics	
L.L.Bean TIDI Skullcandy, HC five BELOW KENNETH COLE	Brad Hildebrand Healthcare Services	Peter Diamond Consumer	Solange Velazquez Data, Software & Analytics	
CORPORATION KERING Jake Autoritie MIRROR Office DEPOT Office Max	LEADERSHIP	PRODUCT	FINANCIAL SPONSORS	GLOBAL NETWORK
	Peter J. Solomon Founder & Chairman	Vinod Chandiramani Head of Capital Advisory	Sash Rentala Financial Sponsors	Azure Capital Cemendocapital
APOLLO OAKHC/FT	Marc Cooper CEO	Jeff Jacobs Head of M&A and COO of IB	Tucker Laurens Financial Sponsors	CLIPPERTON Fenchurch
RHÔNE VESTAR Madryn Healthfoorntcapital R OUNDTABLE CCMP _{capital}	Ken Baronoff Vice Chairman	Joseph Stein Head of Financial Advisory		NATIXIS PARTNERS 傑 VERMILION



CONSUMER HEALTHTECH COVERAGE

FOCUSED B2B2C AND B2C COVERAGE AT THE NEXUS OF DIGITAL HEALTH AND CONSUMER TECH

HEALTHCARE COVERAGE	CONSUMER HEALTHTECH COVERAGE	CONSUMER RETAIL COVERAGE					
🚔 Medical Technology & Devices	Reare Management B2B2C	👷 Beauty, Health & Wellness					
🤪 Healthcare Services	Corporate Wellness	🐁 Branded Apparel, Footwear & Accessories					
Healthcare Technology	🔯 Virtual Care	Consumer Products					
📓 Outsourced Device / Pharma Services	📮 Consumer Med Tech	🕎 E-commerce & Traditional Retail					
Consumer Healthcare	🔄 Health & Wellness Tech	Food, Beverage & Pet					
Eventual Experimentary Life Sciences / Nuclear Medicine	Connected Health & Fitness Devices	Grocery, Pharmacy & Restaurants					
Technology & Media Coverage							




WORLD CLASS EXPERTISE IN CONSUMER HEALTHTECH

Expertise Across:

OLOMON

PARTNERS

- High Growth Consumer Healthtech Verticals
- Customer Channel (DTC, Wholesale, Self-Insured Employer, Payer, Provider)
- Solutions (Software, Tech-Enabled Service, Medical Device, Consumer Product)
- Client Ownership (Founder-owned, PE/VC-backed, Publicly Listed)
- Advisory Role (Sellside, Buyside, Capital Raise, deSPAC, Restructuring)



This document is a marketing presentation. It has been prepared by personnel of Solomon Partners or its affiliates and not by Natixis' research department. It is not investment research or a research recommendation and is not intended to constitute a sufficient basis upon which to make an investment decision. This material is provided for information purposes, is intended for your use only and does not constitute an invitation or offer to subscribe for or purchase any of the products or services mentioned. Any pricing information provided is indicative only and does not represent a level at which an actual trade could be executed. Natixis may trade as principal or have proprietary positions in securities or other financial instruments that are the subject of this material. It is intended only to provide observations and views of the said personnel, which may be different from, or inconsistent with, the observations and views of Natixis analysts or other Natixis sales and/or trading personnel, or the proprietary positions of Natixis. Observations and views of the writer may change at any time without notice.

This presentation may contain forward-looking statements and comments relating to the objectives and strategy of Solomon Partners. Any such projections inherently depend on assumptions, project considerations, objectives and expectations linked to future events, transactions, products and services as well as on suppositions regarding future performance and synergies.

Certain information in this presentation relating to parties other than Solomon Partners or taken from external sources has not been subject to independent verification, and Solomon Partners makes no warranty as to the accuracy, fairness or completeness of the information or opinions in this presentation. Neither Solomon Partners nor its representatives shall be liable for any errors or omissions or for any harm resulting from the use of this presentation, the content of this presentation, or any document or information referred to in this presentation.

Nothing in this presentation constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances. Each individual or entity who receives this document or participates in any future transaction shall be responsible for obtaining all such advice as it thinks appropriate on such matters and shall be responsible for making its own independent investigation and appraisal of the risks, benefits and suitability of the transactions as to itself. Any discussions of past performance should not be taken as an indication of future results, and no representation, expressed or implied, is made regarding future results. No person shall have any liability whatsoever (in negligence or otherwise) for any loss arising from any use of this document or its contents or otherwise arising in connection with this document or any other written or oral communications transmitted to the recipient in relation hereto.

Solomon Partners and/or its affiliates, officers, directors and employees, including persons involved in the preparation or issuance of this material, may, from time to time, have long or short positions in, and buy or sell, the securities or derivatives mentioned in this material.

The information contained herein may be based in part on hypothetical assumptions and for certain models, past performance. These assumptions have certain inherent limitations, and will be affected by any changes in the structure or assets for this transaction. This material is confidential and any redistribution is prohibited. Solomon Partners is not responsible for any unauthorized redistribution.

